EUCTR2019-003763-22-GB进行中（未招募）1 期
A Pragmatic Proof of Concept Study to Evaluate the Effect of Benralizumab on Mannitol Challenge in Severe Eosinophilic Asthma - Benralizumab in Severe Asthma (BISA) version 2.0
Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside0 个研究点目标入组 18 人开始时间: 2020年2月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients aged 18 to 75 years with severe GINA defined asthma
- •Taking a medium to high dose of ICS/LABA OR high dose ICS with another second line controller (BDP equivalent dose of =800µg) of step 4/5 GINA therapy.
- •Established diagnosis of persistent asthma for at least 6 months according to GINA guidelines. Diagnosis should have been properly documented at the screening visit, based on medical documentation and medical history.
- •Uncontrolled asthma as per ACQ6 = 1.5
- •Forced Expiratory Volume in 1 second (FEV1) = 50% predicted.
- •Mannitol PD10 = 635mg at screening and Visit 1
- •Patients with or without nasal polyposis
- •Eosinophilic asthma as evidenced by
- •oEos =300 cells/µl at screening visit or within 6 months prior to screening OR
- •oEos =150 cells/µl at screening visit or within 6 months prior to screening with nasal polyps OR
- •oEos = 150 cells/µl with late onset asthma or fixed airflow obstruction.
- •Ability to give informed consent.
- •Agreement for their GP to be made aware of study participation and to receive feedback as relevant to the participant’s well being.
- •Able to understand the study procedures and the risks involved.
- •Good physical and mental status, determined on the basis of the medical history and a general clinical examination at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Previously been treated with benralizumab.
- •Any other respiratory diseases such as COPD and moderate to severe bronchiectasis which in the opinion of the investigator are considered to be clinically significant and may have an impact on the study outcomes. Patients with Asthma COPD Overlap (ACO) may be included providing they meet all the other criteria.
- •Active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases).
- •Any known systemic (e.g., blood, liver, kidney, etc.) clinically significant medical condition, known significant laboratory abnormalities or communicable disease that may endanger the health or safety of the patient.
- •Asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month prior to screening visit or 3 months if hospital admission was required.
- •Any disorder that is not stable in the opinion of the Investigator.
- •Patients who are participating in the clinical phase of another interventional trial or have done so within the last 30 days or within 5 half-lives of the previous administered product (whichever is longer) before screening. Individuals who are participating in the follow-up phase of another interventional trial, or who are enrolled in an observational study, will be co-enrolled where the Coordinating Investigator of each study agree that it is appropriate.
- •Female patients who are pregnant or lactating.
- •Patients unable or unwilling to consent.
- •Patients taking non-permitted medications.
- •Patients with a history of hypersensitivity to any of the study medications components or a history of other allergy that in the opinion of the investigator contraindicates the patient’s participation.
研究者
相似试验
进行中（未招募）
3 期
The effect of dupilumab on airway twitchiness in severe asthmaAdult patients with severe asthma with type 2 inflammationRespiratoryISRCTN70810039niversity of Dundee20
尚未招募
1 期
Extended intensive care in cases of brain death due to traumatic brain injury having diffuse axonal injuryCTRI/2021/06/033958Himanshu Bansal Foundation
进行中（未招募）
1 期
A Proof of Concept Study to Investigate the use of Simvastatin as a Putative Anti-inflammatory Agent in Asthma - Simvastatin in AsthmaAsthmaEUCTR2005-001466-14-GBniversity of Dundee20
已完成
不适用
How well does the plastic detection comb (PDC) remove nits?ISRCTN72989363KSL Consulting (Denmark)25
进行中（未招募）
1 期
A Proof Of Concept Study To Investigate The Potential Role Of Acetylsalicyclic Acid (Aspirin) As An Anti-Inflammatory Agent For The Treatment Of Asthma - Aspirin as an anti-inflammatory agent in the treatment of asthmaAsthmaEUCTR2005-005622-31-GBniversity of Dundee20